Management of Hot Flashes and Anxiety

Primary Recommendations

The National Comprehensive Cancer Network recommends venlafaxine 75 mg daily as the optimal first-line psychiatric medication for patients experiencing both hot flashes and anxiety, offering a 61% reduction in hot flash severity and treating anxiety symptoms 1
Venlafaxine should be started at 37.5 mg daily and increased to 75 mg after one week, as this dosing strategy balances efficacy with tolerability while providing incremental improvement over lower doses, according to the National Comprehensive Cancer Network 2
The American College of Physicians and the National Comprehensive Cancer Network support venlafaxine as a preferred non-hormonal option for managing hot flashes and anxiety, due to its dual serotonin-norepinephrine mechanism and lack of CYP2D6 inhibition 1, 2

Sertraline 50 mg daily is the preferred SSRI option when SNRIs are contraindicated or not tolerated, particularly in tamoxifen users, as it has weak or no CYP2D6 effects and treats anxiety effectively 1
Gabapentin 900 mg daily provides a 46% reduction in hot flash severity and may be particularly useful when anxiety is mild or when psychiatric medications are contraindicated, with divided dosing improving tolerability 1, 2

The National Comprehensive Cancer Network advises against using paroxetine or fluoxetine in patients taking tamoxifen, as these agents significantly inhibit CYP2D6 and reduce tamoxifen's conversion to its active metabolite, potentially compromising breast cancer treatment efficacy 1
Gradual tapering of SSRIs or SNRIs is necessary to prevent withdrawal symptoms, including dizziness, nausea, and mood disturbances, as recommended by the American Psychiatric Association 1

Fezolinetant represents a newer non-psychiatric alternative that avoids the 10-20% treatment withdrawal rate seen with SSRIs/SNRIs and doesn't require gradual discontinuation, with no CYP2D6 interactions with tamoxifen and a more targeted mechanism specific to hot flash pathophysiology 3